Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
02/2003
02/20/2003WO2002085871A3 Serotonergic agents with long-acting in vivo effects
02/20/2003WO2002085368A3 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
02/20/2003WO2002085291A3 Nociceptin analogs
02/20/2003WO2002083733A3 Polynucleotides and polypeptides of the ifnalpha-6 gene
02/20/2003WO2002078602A3 Transdermal delivery of pergolide
02/20/2003WO2002076437A3 Methods for treating neurodegenerative diseases including alzheimer's
02/20/2003WO2002074742A3 Cdk-inhibitory indirubin derivatives having an increased solubility
02/20/2003WO2002072585A3 Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics
02/20/2003WO2002072003A3 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour
02/20/2003WO2002068399B1 Aryl carbamate derivatives, preparation and use thereof
02/20/2003WO2002065979A3 (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes
02/20/2003WO2002064126A3 Method of treating of demyelinating diseases or conditions
02/20/2003WO2002064109A3 Mucoadhesive pharmaceutical formulations
02/20/2003WO2002058637A3 Compositions and methods for diagnosis of neuropsychiatric disorders
02/20/2003WO2002049993A3 High affinity small molecule c5a receptor modulators
02/20/2003WO2002047730A8 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins
02/20/2003WO2002043731A3 Treatments for neurogenetic disorders, impulse control disorders, and wound healing
02/20/2003WO2002032842A9 Compounds with high monoamine transporter affinity
02/20/2003WO2002030882A9 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
02/20/2003WO2002030860A9 Ketone compounds and compositions for cholesterol management and related uses
02/20/2003WO2002029088A9 Highly expressible genes
02/20/2003WO2002026950A3 Transferases
02/20/2003WO2002024158A8 Pulmonary delivery in treating disorders of the central nervous system
02/20/2003WO2002008268A3 Leucine-based motif and clostridial neurotoxins
02/20/2003WO2001072325A9 Methods of blocking tissue destruction by autoreactive t cells
02/20/2003US20030036652 Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines
02/20/2003US20030036633 DNA encoding bradykinin B1 receptor
02/20/2003US20030036558 Useful in the treatment of chronic complications arising from diabetes, such as neuropathy; may also contain an angiotensin converting enzyme inhibitor.
02/20/2003US20030036556 Zonisamide use in headache
02/20/2003US20030036553 Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
02/20/2003US20030036552 Novel compounds
02/20/2003US20030036551 Aryl or heteroaryl-substituted tetrahydroisoquinoline derivates possess anti-convulsant activity and are therefore believed to be useful in the treatment and/or prevention of many diseases
02/20/2003US20030036549 Methods for treating irritable bowel syndrome
02/20/2003US20030036548 Method for treating anhedonia using dopamine agonists
02/20/2003US20030036545 (6-aryl-pyrrolo(2,3-d)pyrimidin-4-yl)amine derivatives; treating Parkinson's disease and diseases associated with locomotor activity, vasodilation, platelet inhibition, neutrophil superoxide generation, cognitive disorders, etc.
02/20/2003US20030036543 Especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
02/20/2003US20030036536 Substituted benzylthioacetic acids and esters
02/20/2003US20030036507 Urocortin-III and uses thereof
02/20/2003US20030036112 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of nervous system and tumor disorders
02/20/2003US20030035837 Mixture of drug with retarder; sustained release
02/20/2003US20030035835 Protective overcoatings
02/20/2003US20030035832 Compression of drug and adjuvant
02/20/2003US20030035831 Pharmaceutical compositions for buccal delivery of pain relief medications
02/20/2003CA2457622A1 Kavalactone compositions and methods of use
02/20/2003CA2457314A1 Percutaneous absorption preparations
02/20/2003CA2456964A1 Melanin-concentrating hormone antagonists
02/20/2003CA2456942A1 Compositions and methods for modulation of darpp-32 phosphorylation
02/20/2003CA2456939A1 Carbonic anhydrase inhibitors
02/20/2003CA2456762A1 Interleukin-1 receptors in the treatment of diseases
02/20/2003CA2456744A1 Adenosine a3 receptor agonists
02/20/2003CA2456599A1 Spiro compounds
02/20/2003CA2456594A1 Preventives/remedies for cholinergic neuropathy
02/20/2003CA2456533A1 Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs
02/20/2003CA2456369A1 Proteins associated with cell growth, differentiation, and death
02/20/2003CA2456322A1 Compositions and methods to prevent abuse of opioids
02/20/2003CA2456291A1 Hydroxamic acid derivatives
02/20/2003CA2456250A1 Arylsulfonyl derivatives with 5-ht6 receptor affinity
02/20/2003CA2456175A1 Benzoquinone ansamycins
02/20/2003CA2456124A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists
02/20/2003CA2456103A1 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives
02/20/2003CA2455871A1 Substituted pyridin-4-ones and their use as gonadotropin-releasing hormone receptor antagonists.
02/20/2003CA2455861A1 Sulfonamide derivatives as gamma secretase inhibitors
02/20/2003CA2455761A1 Artichoke leaf extracts
02/20/2003CA2455759A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
02/20/2003CA2455754A1 Amine derivatives
02/20/2003CA2455631A1 Aminoisoxazole derivatives active as kinase inhibitors
02/20/2003CA2455585A1 Compounds for treating anhedonia
02/20/2003CA2455424A1 Compositions and methods for the prevention and treatment of huntington's disease
02/20/2003CA2455420A1 Compositions and methods to prevent abuse of opioids
02/20/2003CA2455336A1 Peptides that bind to atherosclerotic lesions
02/20/2003CA2454648A1 Irinotecan for treatment of cancer
02/20/2003CA2454643A1 Methods for the treatment of cancer with irinotecan based on cyp3a5
02/20/2003CA2454640A1 Methods for treatment of cancer using irinotecan based on ugt1a1
02/20/2003CA2454637A1 Use of irinotecan for improved treatment of cancer based on mdr1
02/20/2003CA2454627A1 Methods for improved treatment of cancer with irinotecan based on mrp1
02/20/2003CA2454417A1 Novel benzo-fused heterocycles as endothelin antagonists
02/20/2003CA2454251A1 Isolation and mobilization of stem cells expressing vegfr-1
02/20/2003CA2453890A1 Crystal and process for producing the same
02/20/2003CA2453537A1 Therapeutic 1h-pyrido¬4,3-b|indoles
02/20/2003CA2453506A1 Pramipexole as an anticonvulsant
02/20/2003CA2453485A1 Pramipexole for the treatment of adhd
02/20/2003CA2453433A1 Methods of use for novel sulfur containing organic nitrate compounds
02/20/2003CA2453219A1 Therapeutically useful tetracyclic ligands
02/20/2003CA2451919A1 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof
02/20/2003CA2451914A1 Combination therapy for the treatment of neurological disorders
02/20/2003CA2451691A1 Use of r-nsaid compounds for anti-hiv treatment
02/19/2003WO2002016574A2 Method for identifying peptides that can be specifically cleaved and the use of peptide sequences of this type
02/19/2003EP1284423A2 Adrenic acid (delta 7,10,13,16 docosatetraenoic acid ) receptor and uses thereof
02/19/2003EP1284265A1 Benzothiophene derivatives and medicinal use thereof
02/19/2003EP1284257A2 Difluoromethylene aromatic ethers and their use as inhibitors of the glycine type-1 transporter
02/19/2003EP1284141A2 Pharmaceutical combinations comprising neuronal nitric oxide synthase inhibitors for the treatment of neurodegenerative diseases
02/19/2003EP1283886A2 Intracellular signaling proteins
02/19/2003EP1283848A2 Protein complexes and assays for screening anti-cancer agents
02/19/2003EP1283839A1 Adenosine a2a receptor antagonists
02/19/2003EP1283838A1 Piperazine and piperidine compounds
02/19/2003EP1283836A2 Neuroprotective and anti-proliferative compounds
02/19/2003EP1283835A2 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators
02/19/2003EP1283834A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
02/19/2003EP1283833A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
02/19/2003EP1283832A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
1 ... 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 ... 1833